Ashley A Leech1,2,3, James F Burgess3,4, Meg Sullivan5,6, Wendy Kuohung7, Michal Horný3,8,9, Mari-Lynn Drainoni3,4,6,10, Cindy L Christiansen11, Benjamin P Linas5,6. 1. Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee. 2. Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. 3. Department of Health Law, Policy and Management, Boston University School of Public Health. 4. U.S. Department of Veterans Affairs, Center for Healthcare Organization and Implementation Research. 5. Department of Medicine, Center for Infectious Diseases, Boston Medical Center. 6. Department of Medicine, Section of Infectious Diseases. 7. Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, Massachusetts. 8. Department of Radiology and Imaging Sciences, Emory University School of Medicine. 9. Department of Health Policy and Management, Emory University Rollins School of Public Health, Atlanta, Georgia. 10. Evans Center for Implementation and Improvement Sciences, Boston University. 11. Boston University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: The aim of this study was to investigate the value of coformulated Tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) for conception in the U.S. and to identify scenarios in which 'Undetectable = Untransmittable' (U = U) may not be adequate, and rather, PrEP or assisted reproduction would improve outcomes. DESIGN: We developed a Markov cohort simulation model to estimate the incremental benefits and cost-effectiveness of PrEP compared with alternative safer conception strategies, including combination antiretroviral therapy (cART) alone for the HIV-infected partner and assisted reproductive technologies. We modelled various scenarios in which HIV RNA suppression in the male partner was less than perfect. SETTING: U.S. healthcare sector perspective. PARTICIPANTS: Serodiscordant couples in the U.S. was composed of an HIV-infected male and HIV-uninfected female seeking conception. INTERVENTION: Economic analysis. MAIN OUTCOME MEASURE(S): Cumulative risks of HIV transmission to women and babies, maternal life expectancy, discounted quality-adjusted life years (QALY), discounted lifetime medical costs and incremental cost-effectiveness ratios. RESULTS: cART with condomless intercourse limited to ovulation was the preferred HIV prevention strategy among women seeking to conceive with an HIV-infected partner who is HIV-suppressed. PrEP was not cost-effective for women who had partners who were virologically suppressed. When the probability of male partner HIV suppression was low and we assumed generic pricing of PrEP, PrEP was cost-effective, and sometimes even cost-saving compared with cART alone. CONCLUSION: From a U.S. healthcare sector perspective, when the male partner was not reliably suppressed, PrEP became economically attractive, and in some cases, cost-saving.
OBJECTIVE: The aim of this study was to investigate the value of coformulated Tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) for conception in the U.S. and to identify scenarios in which 'Undetectable = Untransmittable' (U = U) may not be adequate, and rather, PrEP or assisted reproduction would improve outcomes. DESIGN: We developed a Markov cohort simulation model to estimate the incremental benefits and cost-effectiveness of PrEP compared with alternative safer conception strategies, including combination antiretroviral therapy (cART) alone for the HIV-infected partner and assisted reproductive technologies. We modelled various scenarios in which HIV RNA suppression in the male partner was less than perfect. SETTING: U.S. healthcare sector perspective. PARTICIPANTS: Serodiscordant couples in the U.S. was composed of an HIV-infected male and HIV-uninfected female seeking conception. INTERVENTION: Economic analysis. MAIN OUTCOME MEASURE(S): Cumulative risks of HIV transmission to women and babies, maternal life expectancy, discounted quality-adjusted life years (QALY), discounted lifetime medical costs and incremental cost-effectiveness ratios. RESULTS: cART with condomless intercourse limited to ovulation was the preferred HIV prevention strategy among women seeking to conceive with an HIV-infected partner who is HIV-suppressed. PrEP was not cost-effective for women who had partners who were virologically suppressed. When the probability of male partner HIV suppression was low and we assumed generic pricing of PrEP, PrEP was cost-effective, and sometimes even cost-saving compared with cART alone. CONCLUSION: From a U.S. healthcare sector perspective, when the male partner was not reliably suppressed, PrEP became economically attractive, and in some cases, cost-saving.
Authors: Laurence S Magder; Lynne Mofenson; Mary E Paul; Carmen D Zorrilla; William A Blattner; Ruth E Tuomala; Phil LaRussa; Sheldon Landesman; Kenneth C Rich Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: Cora L Bernard; Margaret L Brandeau; Keith Humphreys; Eran Bendavid; Mark Holodniy; Christopher Weyant; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: Ann Intern Med Date: 2016-04-26 Impact factor: 51.598
Authors: Ashley A Leech; Dea Biancarelli; Erika Aaron; Emily S Miller; Jenell S Coleman; Peter L Anderson; Hervette Nkwihoreze; Brianne Condron; Meg Sullivan Journal: AIDS Patient Care STDS Date: 2020-07 Impact factor: 5.078